Search

Your search keyword '"Carratalà, J."' showing total 625 results
Start Over Author "Carratalà, J."
625 results on '"Carratalà, J."'

4. Risk factors and prognosis of complicated urinary tract infections caused by Pseudomonas aeruginosa in hospitalized patients: a retrospective multicenter cohort study

Author

Gomila A, Carratalà J, Eliakim-Raz N, Shaw E, Wiegand I, Vallejo-Torres L, Gorostiza A, Vigo JM, Morris S, Stoddart M, Grier S, Vank C, Cuperus N, van den Heuvel L, Vuong C, MacGowan A, Leibovici L, Addy I, and Pujol M

Subjects
healthcare associated-infections, complicated urinary tract infections, Pseudomonas aeruginosa, multidrug-resistance., Infectious and parasitic diseases, RC109-216
Abstract

Aina Gomila,1,2 J Carratalà,1–3 N Eliakim-Raz,4 E Shaw,1,2 I Wiegand,5 L Vallejo-Torres,6 A Gorostiza,2 JM Vigo,7 S Morris,6 M Stoddart,8 S Grier,8 C Vank,5 N Cuperus,9 L Van den Heuvel,9 C Vuong,5 A MacGowan,8 L Leibovici,4 I Addy,5 M Pujol1,2 On behalf of COMBACTE MAGNET WP5 RESCUING Study Group and Study Sites 1Department of Infectious Diseases, Hospital Universitari de Bellvitge, Institut Català de la Salut (ICS-HUB), Spanish Network for Research in Infectious Diseases (REIPI RD12/0015), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; 2Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain; 3Infectious Diseases Department, University of Barcelona, Barcelona, Spain; 4Department of Medicine E, Beilinson Hospital, Rabin Medical Center, Petah-Tiqva and Sackler Faculty of Medicine, Tel Aviv University, Israel; 5AiCuris Anti-infective Cures, Wuppertal, Germany; 6UCL Department of Applied Health Research, University College London, London, UK; 7Informatics Unit, Fundació Institut Català de Farmacologia, Barcelona, Spain; 8Department of Medical Microbiology, Southmead Hospital, North Bristol NHS Trust, Bristol, UK; 9Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands Purpose: Complicated urinary tract infections (cUTIs) are among the most frequent health-care-associated infections. In patients with cUTI, Pseudomonas aeruginosa deserves special attention, since it can affect patients with serious underlying conditions. Our aim was to gain insight into the risk factors and prognosis of P. aeruginosa cUTIs in a scenario of increasing multidrug resistance (MDR). Methods: This was a multinational, retrospective, observational study at 20 hospitals in south and southeastern Europe, Turkey, and Israel including consecutive patients with cUTI hospitalized between January 2013 and December 2014. A mixed-effect logistic regression model was performed to assess risk factors for P. aeruginosa and MDR P. aeruginosa cUTI.Results: Of 1,007 episodes of cUTI, 97 (9.6%) were due to P. aeruginosa. Resistance rates of P. aeruginosa were: antipseudomonal cephalosporins 35 of 97 (36.1%), aminoglycosides 30 of 97 (30.9%), piperacillin–tazobactam 21 of 97 (21.6%), fluoroquinolones 43 of 97 (44.3%), and carbapenems 28 of 97 (28.8%). The MDR rate was 28 of 97 (28.8%). Independent risk factors for P. aeruginosa cUTI were male sex (OR 2.61, 95% CI 1.60–4.27), steroid therapy (OR 2.40, 95% CI 1.10–5.27), bedridden functional status (OR 1.79, 95% CI 0.99–3.25), antibiotic treatment within the previous 30 days (OR 2.34, 95% CI 1.38–3.94), indwelling urinary catheter (OR 2.41, 95% CI 1.43–4.08), and procedures that anatomically modified the urinary tract (OR 2.01, 95% CI 1.04–3.87). Independent risk factors for MDR P. aeruginosa cUTI were age (OR 0.96, 95% CI 0.93–0.99) and anatomical urinary tract modification (OR 4.75, 95% CI 1.06–21.26). Readmission was higher in P. aeruginosa cUTI patients than in other etiologies (23 of 97 [23.7%] vs 144 of 910 [15.8%], P=0.04), while 30-day mortality was not significantly different (seven of 97 [7.2%] vs 77 of 910 [8.5%], P=0.6).Conclusion: Patients with P. aeruginosa cUTI had characteristically a serious baseline condition and manipulation of the urinary tract, although their mortality was not higher than that of patients with cUTI caused by other etiologies. Keywords: health care-associated infections, complicated urinary tract infections, Pseudomonas aeruginosa, multidrug-resistance

Published
2018

6. Multinational case-control study of risk factors for the development of late invasive pulmonary aspergillosis following kidney transplantation

Author

López-Medrano, F., Fernández-Ruiz, M., Silva, J.T., Carver, P.L., van Delden, C., Merino, E., Pérez-Saez, M.J., Montero, M., Coussement, J., de Abreu Mazzolin, M., Cervera, C., Santos, L., Sabé, N., Scemla, A., Cordero, E., Cruzado-Vega, L., Martín-Moreno, P.L., Len, Ó., Rudas, E., Ponce de León, A., Arriola, M., Lauzurica, R., David, M.D., González-Rico, C., Henríquez-Palop, F., Fortún, J., Nucci, M., Manuel, O., Paño-Pardo, J.R., Montejo, M., Vena, A., Sánchez-Sobrino, B., Mazuecos, A., Pascual, J., Horcajada, J.P., Lecompte, T., Moreno, A., Carratalà, J., Blanes, M., Hernández, D., Hernández-Méndez, E.A., Fariñas, M.C., Perelló-Carrascosa, M., Muñoz, P., Andrés, A., and Aguado, J.M.

Published
2018
Full Text
View/download PDF

9. Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE)

Author

Laporte-Amargos, J., Gudiol, C., Arnan, M., Puerta-Alcalde, P., Carmona-Torre, F., Huguet, M., Albasanz-Puig, A., Parody, R., Garcia-Vidal, C., del Pozo, J. L., Batlle, M., Tebé, C., Rigo-Bonnin, R., Muñoz, C., Padullés, A., Tubau, F., Videla, S., Sureda, A., and Carratalà, J.

Published
2020
Full Text
View/download PDF

10. Clinical Presentation and Determinants of Mortality of Invasive Pulmonary Aspergillosis in Kidney Transplant Recipients: A Multinational Cohort Study

Author

López-Medrano, F., Fernández-Ruiz, M., Silva, J.T., Carver, P.L., van Delden, C., Merino, E., Pérez-Saez, M.J., Montero, M., Coussement, J., de Abreu Mazzolin, M., Cervera, C., Santos, L., Sabé, N., Scemla, A., Cordero, E., Cruzado-Vega, L., Martín-Moreno, P.L., Len, ó., Rudas, E., de León, A.P., Arriola, M., Lauzurica, R., David, M., González-Rico, C., Henríquez-Palop, F., Fortún, J., Nucci, M., Manuel, O., Paño-Pardo, J.R., Montejo, M., Muñoz, P., Sánchez-Sobrino, B., Mazuecos, A., Pascual, J., Horcajada, J.P., Lecompte, T., Moreno, A., Carratalà, J., Blanes, M., Hernández, D., Fariñas, M.C., Andrés, A., and Aguado, J.M.

Published
2016
Full Text
View/download PDF

11. Risk Factors Associated With Early Invasive Pulmonary Aspergillosis in Kidney Transplant Recipients: Results From a Multinational Matched Case–Control Study

Author

López‐Medrano, F., Silva, J.T., Fernández‐Ruiz, M., Carver, P.L., van Delden, C., Merino, E., Pérez‐Saez, M.J., Montero, M., Coussement, J., de Abreu Mazzolin, M., Cervera, C., Santos, L., Sabé, N., Scemla, A., Cordero, E., Cruzado‐Vega, L., Martín‐Moreno, P.L., Len, Ó., Rudas, E., de León, A. Ponce, Arriola, M., Lauzurica, R., David, M., González‐Rico, C., Henríquez‐Palop, F., Fortún, J., Nucci, M., Manuel, O., Paño‐Pardo, J.R., Montejo, M., Muñoz, P., Sánchez‐Sobrino, B., Mazuecos, A., Pascual, J., Horcajada, J.P., Lecompte, T., Lumbreras, C., Moreno, A., Carratalà, J., Blanes, M., Hernández, D., Hernández‐Méndez, E.A., Fariñas, M.C., Perelló‐Carrascosa, M., Morales, J.M., Andrés, A., and Aguado, J.M.

Published
2016
Full Text
View/download PDF

16. Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: a retrospective multicenter case–control study

Author

Clemente, W., Vidal, E., Girão, E., Ramos, A.S.D., Govedic, F., Merino, E., Muñoz, P., Sabé, N., Cervera, C., Cota, G.F., Cordero, E., Mena, A., Montejo, M., López-Medrano, F., Aguado, J.M., Fernandes, P., Valerio, M., Carratalá, J., Moreno, A., Oliveira, J., Mourão, P.H.O., and Torre-Cisneros, J.

Published
2015
Full Text
View/download PDF

22. Correction to: Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies

Author

Moreno-García, E, Puerta-Alcalde, P, Gariup, G, Fernández-Ruiz, M, López Cortés, L E, Cuervo, G, Salavert, M, Merino, P, Machado, M, Guinea, J, García-Rodríguez, J, Garnacho-Montero, J, Cardozo, C, Peman, J, Montejo, M, Fortún, J, Almirante, B, Castro, C, Rodríguez-Baño, J, Aguado, J M, Martínez, J A, Carratalà, J, Soriano, A, and Garcia-Vidal, C

Subjects
Infectious Diseases, Oncology
Abstract

[This corrects the article DOI: 10.1093/ofid/ofab250.].

Published
2022

26. Real-life use of ceftolozane/tazobactam for the treatment of bloodstream infection due to Pseudomonas aeruginosa in neutropenic hematologic patients: a matched control study (ZENITH study)

Author

Bergas, A. (Alba), Albasanz-Puig, A. (Adaia), Fernández-Cruz, A. (Ana), Machado, M. (Marina), Novo, A. (Andrés), Van-Duin, D. (David), Garcia-Vidal, C. (C.), Hakki, M. (Morgan), Ruiz-Camps, I. (Isabel), Pozo, J.L. (José Luis) del, Oltolini, C. (Chiara), DeVoe, C. (Catherine), Drgona, L. (Lubos), Gasch, O. (Oriol), Mikulska, M. (Malgorzata), Martín-Dávila, P. (Pilar), Peghin, M. (Maddalena), Laporte-Amargos, J. (J.), Durà-Miralles, X. (Xavier), Pallarès, N. (Natàlia), González-Barca, E. (Eva), Álvarez-Uría, A. (Ana), Puerta-Alcalde, P. (Pedro), Aguilar-Company, J. (Juan), Carmona-Torre, F. (Francisco de A.), Clerici, T.D. (Teresa Daniela), Doernberg, S.B. (Sarah B.), Petrikova, L. (Lucía), Capilla, S. (Silvia), Magnasco, L. (Laura), Fortún, J. (Jesús), Castaldo, N. (Nadia), Carratalà, J. (Jordi), and Gudiol, C. (Carlota)

Subjects
Hematologic malignancy, Tazobactam, Neutropenia, Epidemiology, Pseudomonas aeruginosa, Multidrug-resistant, Bacteremia, Gram-negative infections, Ceftolozane/Tazobactam, Therapy, Bloodstream infection, Malignancies
Abstract

We sought to assess the characteristics and outcomes of neutropenic hematologic patients with Pseudomonas aeruginosa (PA) bloodstream infection (BSI) treated with ceftolozane-tazobactam (C/T). We conducted a multicenter, international, matched-cohort study of PA BSI episodes in neutropenic hematologic patients who received C/T. Controls were patients with PA BSI treated with other antibiotics. Risk factors for overall 7-day and 30-day case fatality rates were analyzed. We compared 44 cases with 88 controls. Overall, 91% of episodes were caused by multidrug-resistant (MDR) strains. An endogenous source was the most frequent BSI origin (35.6%), followed by pneumonia (25.8%). There were no significant differences in patient characteristics between groups. C/T was given empirically in 11 patients and as definitive therapy in 41 patients. Treatment with C/T was associated with less need for mechanical ventilation (13.6% versus 33.3%; P = 0.021) and reduced 7-day (6.8% versus 34.1%; P = 0.001) and 30-day (22.7% versus 48.9%; P = 0.005) mortality. In the multivariate analysis, pneumonia, profound neutropenia, and persistent BSI were independent risk factors for 30-day mortality, whereas lower mortality was found among patients treated with C/T (adjusted OR [aOR] of 0.19; confidence interval [CI] 95% of 0.07 to 0.55; P = 0.002). Therapy with C/T was associated with less need for mechanical ventilation and reduced 7-day and 30-day case fatality rates compared to alternative agents in neutropenic hematologic patients with PA BSI. IMPORTANCE Ceftolozane-tazobactam (C/T) has been shown to be a safe and effective alternative for the treatment of difficult to treat infections due to Pseudomonas aeruginosa (PA) in the general nonimmunocompromised population. However, the experience of this agent in immunosuppressed neutropenic patients is very limited. Our study is unique because it is focused on extremely immunosuppressed hematological patients with neutropenia and bloodstream infection (BSI) due to PA (mainly multidrug resistant [MDR]), a scenario which is often associated with very high mortality rates. In our study, we found that the use of C/T for the treatment of MDR PA BSI in hematological neutropenic patients was significantly associated with improved outcomes, and, in addition, it was found to be an independent risk factor associated with increased survival. To date, this is the largest series involving neutropenic hematologic patients with PA BSI treated with C/T. Ceftolozane-tazobactam (C/T) has been shown to be a safe and effective alternative for the treatment of difficult to treat infections due to Pseudomonas aeruginosa (PA) in the general nonimmunocompromised population. However, the experience of this agent in immunosuppressed neutropenic patients is very limited.

Published
2022

34. Co-infections and superinfections complicating COVID-19 in cancer patients: a multicentre, international study

Author

Gudiol, C., Durà-Miralles, X., Aguilar-Company, J., Hernández-Jiménez, P., Martínez-Cutillas, M., Fernandez-Avilés, F., Gutiérrez Gutiérrez, Belén, Carratalà, J., and Universidad de Sevilla. Departamento de Medicina

Subjects
Co-infections, COVID-19, Cancer
Abstract

Background: We aimed to describe the epidemiology, risk factors, and clinical outcomes of co-infections and superinfections in onco-hematological patients with COVID-19. Methods: International, multicentre cohort study of cancer patients with COVID-19. All patients were included in the analysis of co-infections at diagnosis, while only patients admitted at least 48 h were included in the analysis of superinfections. Results: 684 patients were included (384 with solid tumors and 300 with hematological malignancies). Co-infections and superinfections were documented in 7.8% (54/684) and 19.1% (113/590) of patients, re- spectively. Lower respiratory tract infections were the most frequent infectious complications, most of- ten caused by Streptococcus pneumoniae and Pseudomonas aeruginosa . Only seven patients developed op- portunistic infections. Compared to patients without infectious complications, those with infections had worse outcomes, with high rates of acute respiratory distress syndrome, intensive care unit (ICU) admis- sion, and case-fatality rates. Neutropenia, ICU admission and high levels of C-reactive protein (CRP) were independent risk factors for infections. Conclusions: Infectious complications in cancer patients with COVID-19 were lower than expected, affect- ing mainly neutropenic patients with high levels of CRP and/or ICU admission. The rate of opportunistic infections was unexpectedly low. The use of empiric antimicrobials in cancer patients with COVID-19 needs to be optimized.

Published
2021

37. Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study

Author

Gudiol, C., primary, Durà-Miralles, X., additional, Aguilar-Company, J., additional, Hernández-Jiménez, P., additional, Martínez-Cutillas, M., additional, Fernandez-Avilés, F., additional, Machado, M., additional, Vázquez, L., additional, Martín-Dávila, P., additional, de Castro, N., additional, Abdala, E., additional, Sorli, L., additional, Andermann, T.M., additional, Márquez-Gómez, I., additional, Morales, H., additional, Gabilán, F., additional, Ayaz, C.M., additional, Kayaaslan, B., additional, Aguilar-Guisado, M., additional, Herrera, F., additional, Royo-Cebrecos, C., additional, Peghin, M., additional, González-Rico, C., additional, Goikoetxea, J., additional, Salgueira, C., additional, Silva-Pinto, A., additional, Gutiérrez-Gutiérrez, B., additional, Cuellar, S., additional, Haidar, G., additional, Maluquer, C., additional, Marin, M., additional, Pallarès, N., additional, and Carratalà, J., additional

Published
2021
Full Text
View/download PDF

38. Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a Propensity-Matched Cohort Study (AMINOLACTAM Study)

Author

Albasanz-Puig, A., primary, Gudiol, C., additional, Puerta-Alcalde, P., additional, Ayaz, C. M., additional, Machado, M., additional, Herrera, F., additional, Martín-Dávila, P., additional, Laporte-Amargós, J., additional, Cardozo, C., additional, Akova, M., additional, Álvarez-Uría, A., additional, Torres, D., additional, Fortún, J., additional, García-Vidal, C., additional, Muñoz, P., additional, Bergas, A., additional, Pomares, H., additional, Mercadal, S., additional, Durà-Miralles, X., additional, García-Lerma, E., additional, Pallarès, N., additional, and Carratalà, J., additional

Published
2021
Full Text
View/download PDF

40. Immunomodulatory therapy, risk factors and outcomes of hospital-acquired bloodstream infection in patients with severe COVID-19 pneumonia: a Spanish case-control matched multicentre study (BACTCOVID)

Author

Abelenda-Alonso G, Rombauts A, Gudiol C, Oriol I, Simonetti A, Coloma A, Rodríguez-Molinero A, Izquierdo E, Vicens Diaz de Brito Fernandez, Montserrat Sanmartí Villamala, Padullés A, Grau I, Ras MM, Bergas A, Guillem L, Blanco-Arévalo A, Alvarez-Pouso C, Pallarés N, Videla S, Tebé C, and Carratalà J

Subjects
Immunomodulatory therapy, Bacteraemia, COVID-19, SARS-CoV-2 pneumonia, bacterial infections and mycoses, human activities, Hospital-acquired infection
Abstract

OBJECTIVES: The effect of the use of immunomodulatory drugs on the risk of developing hospital-acquired bloodstream infection (BSI) in patients with COVID-19 has not been specifically assessed. We aim to identify risk factors for, and outcomes of, BSI among hospitalized patients with severe COVID-19 pneumonia. METHODS: We performed a severity matched case-control study (1:1 ratio) nested in a large multicentre prospective cohort of hospitalized adults with COVID-19. Cases with BSI were identified from the cohort database. Controls were matched for age, sex and acute respiratory distress syndrome. A Cox proportional hazard ratio model was performed. RESULTS: Of 2005 patients, 100 (4.98%) presented 142 episodes of BSI, mainly caused by coagulase-negative staphylococci, Enterococcus faecalis and Pseudomonas aeruginosa. Polymicrobial infection accounted for 23 episodes. The median time from admission to the first episode of BSI was 15 days (IQR 9-20), and the most frequent source was catheter-related infection. The characteristics of patients with and without BSI were similar, including the use of tocilizumab, corticosteroids, and combinations. In the multivariate analysis, the use of these immunomodulatory drugs was not associated with an increased risk of BSI. A Cox proportional hazard ratio (HR) model showed that after adjusting for the time factor, BSI was associated with a higher in-hospital mortality risk (HR 2.59; 1.65-4.07; p < 0.001). DISCUSSION: Hospital-acquired BSI in patients with severe COVID-19 pneumonia was uncommon and the use of immunomodulatory drugs was not associated with its development. When adjusting for the time factor, BSI was associated with a higher mortality risk.

Published
2021

41. Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients

Author

Pierrotti, L. C, Pérez-Nadales, E., Fernández-Ruiz, M., Gutiérrez Gutiérrez, Belén, Tan, B. H., Carratalà, J., Cordero Matia, María Elisa, Pascual Hernández, Álvaro, Rodríguez-Baño, Jesús, Aguado, J. M., Universidad de Sevilla. Departamento de Medicina, and Universidad de Sevilla. Departamento de Microbiología

Subjects
Kidney transplantation, Urinary tract infection, Carbapenem-sparing regimen, Extended-spectrum β-lactamase-producing Enterobacterales, Outcomes, Bloodstream infection
Abstract

Background Whether active therapy with β-lactam/β-lactamase inhibitors (BLBLI) is as affective as carbapenems for extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) bloodstream infection (BSI) secondary to urinary tract infection (UTI) in kidney transplant recipients (KTRs) remains unclear. Methods We retrospectively evaluated 306 KTR admitted to 30 centers from January 2014 to October 2016. Therapeutic failure (lack of cure or clinical improvement and/or death from any cause) at days 7 and 30 from ESBL-E BSI onset was the primary and secondary study outcomes, respectively. Results Therapeutic failure at days 7 and 30 occurred in 8.2% (25/306) and 13.4% (41/306) of patients. Hospital-acquired BSI (adjusted OR [aOR]: 4.10; 95% confidence interval [CI]: 1.50-11.20) and Pitt score (aOR: 1.47; 95% CI: 1.21-1.77) were independently associated with therapeutic failure at day 7. Age-adjusted Charlson Index (aOR: 1.25; 95% CI: 1.05-1.48), Pitt score (aOR: 1.72; 95% CI: 1.35-2.17), and lymphocyte count ≤500 cells/μL at presentation (aOR: 3.16; 95% CI: 1.42-7.06) predicted therapeutic failure at day 30. Carbapenem monotherapy (68.6%, primarily meropenem) was the most frequent active therapy, followed by BLBLI monotherapy (10.8%, mostly piperacillin-tazobactam). Propensity score (PS)-adjusted models revealed no significant impact of the choice of active therapy (carbapenem-containing vs any other regimen, BLBLI- vs carbapenem-based monotherapy) within the first 72 hours on any of the study outcomes. Conclusions Our data suggest that active therapy based on BLBLI may be as effective as carbapenem-containing regimens for ESBL-E BSI secondary to UTI in the specific population of KTR. Potential residual confounding and unpowered sample size cannot be excluded

Published
2021

44. Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies

Author

Moreno-García, E, primary, Puerta-Alcalde, P, additional, Gariup, G, additional, Fernández-Ruiz, M, additional, López Cortés, L E, additional, Cuervo, G, additional, Salavert, M, additional, Merino, P, additional, Machado, M, additional, Guinea, J, additional, García-Rodríguez, J, additional, Garnacho-Montero, J, additional, Cardozo, C, additional, Peman, J, additional, Montejo, M, additional, Fortún, J, additional, Almirante, B, additional, Castro, C, additional, Rodríguez-Baño, J, additional, Aguado, J M, additional, Martínez, J A, additional, Carratalà, J, additional, Soriano, A, additional, and Garcia-Vidal, C, additional

Published
2021
Full Text
View/download PDF

48. Influenza vaccination during the first 6 months after solid organ transplantation is efficacious and safe

Author

Alamo, J.M., Gasch, A., Gentil-Govantes, M.A., Molina-Ortega, F.J., Lage, E., Martínez-Atienza, J., Sánchez, M., Rosso, C., Arizón, J.M., Aguera, M., Cantisán, S., Montero, J.L., Páez, A., Rodríguez, A., Santos, S., Vidal, E., Berasategui, C., Campins, M., López-Meseguer, M., Saez, B., Marcos, M.A., Sanclemente, G., Diez, N., Goikoetxea, J., Casafont, F., Cobo-Beláustegy, M., Durán, R., Fábrega-García, E., Fernández-Rozas, S., González-Rico, C., Zurbano-Goñi, F., Bodro, M., Niubó, J., Oriol, S., Sabé, N., Anaya, F., Bouza, E., Catalán, P., Diez, P., Eworo, A., Kestler, M., Lopez-Roa, P., Rincón, D., Rodríguez, M., Salcedo, M., Sousa, Y., Valerio, M., Morales-Barroso, I., Aguado, J.M., Origuen, J., Pérez-Romero, P., Bulnes-Ramos, A., Torre-Cisneros, J., Gavaldá, J., Aydillo, T.A., Moreno, A., Montejo, M., Fariñas, M.C., Carratalá, J., Muñoz, P., Blanes, M., Fortún, J., Suárez-Benjumea, A., López-Medrano, F., Barranco, J.L., Peghin, M., Roca, C., Lara, R., and Cordero, E.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results